How High Will Eli Lilly Stock Go By 2030?
The weight loss drugs market is heating up quickly and…
Sell
44
ORGO Quote, Financials, Valuation and Earnings
Last price:
$4.34
Seasonality move
:
4.52%
Day range:
$4.14 - $4.28
52-week range:
$2.17 - $6.71
Dividend yield:
0%
P/E ratio:
70.39x
P/S ratio:
1.15x
P/B ratio:
2.03x
Volume:
636.3K
Avg. volume:
1.3M
1-year change:
45.17%
Market cap:
$533.9M
Revenue:
$482M
EPS (TTM):
-$0.02
Analysts' Opinion
-
Consensus RatingOrganogenesis Holdings has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.00, Organogenesis Holdings has an estimated upside of 42.52% from its current price of $4.21.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $4.21.
Fair Value
-
According to the consensus of 4 analysts, Organogenesis Holdings has 42.52% upside to fair value with a price target of $6.00 per share.
ORGO vs. S&P 500
-
Over the past 5 trading days, Organogenesis Holdings has overperformed the S&P 500 by 1.08% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Organogenesis Holdings does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Organogenesis Holdings has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Organogenesis Holdings reported revenues of $126.7M.
Earnings Growth
-
Organogenesis Holdings has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Organogenesis Holdings reported earnings per share of $0.04.
Enterprise value:
520.8M
EV / Invested capital:
--
Price / LTM sales:
1.15x
EV / EBIT:
24.27x
EV / Revenue:
1.08x
PEG ratio (5yr expected):
--
EV / Free cash flow:
124.71x
Price / Operating cash flow:
133.08x
Enterprise value / EBITDA:
33.04x
Gross Profit (TTM):
$366.3M
Return On Assets:
0.19%
Net Income Margin (TTM):
0.18%
Return On Equity:
0.29%
Return On Invested Capital:
0.25%
Operating Margin:
8.07%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $450.9M | $433.1M | $482M | $99.7M | $126.7M | |
| Gross Profit | $345.9M | $326.7M | $366.3M | $71.9M | $95.6M | |
| Operating Income | $22.3M | $12.5M | $21.5M | -$1.3M | $10.2M | |
| EBITDA | $33M | $27.9M | $15.8M | $2.9M | $14.6M | |
| Diluted EPS | $0.12 | $0.04 | -$0.02 | -$0.00 | $0.04 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $174.3M | $227M | $222.6M | $225M | $285.9M | |
| Total Assets | $290.2M | $443.3M | $449.4M | $460M | $497.9M | |
| Current Liabilities | $68.2M | $82.7M | $75M | $80.5M | $77.5M | |
| Total Liabilities | $148.4M | $201.9M | $183.7M | $181.4M | $112.6M | |
| Total Equity | $141.8M | $241.3M | $265.7M | $278.7M | $385.3M | |
| Total Debt | $69.7M | $73.4M | $70.8M | $66.2M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $24.9M | $30.9M | $14.2M | $10.6M | $10.9M | |
| Cash From Investing | -$33.9M | -$24.4M | -$10M | -$3.3M | -$3.4M | |
| Cash From Financing | -$2.2M | -$5.5M | $27.6M | -$1.8M | $33.6M | |
| Free Cash Flow | -$9M | $6.6M | $4.2M | $7.3M | $7.6M | |
ORGO
Sector
Market Cap
$533.9M
$34.2M
Price % of 52-Week High
62.74%
42.23%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
45.17%
-41.76%
Beta (5-Year)
1.795
0.737
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$4.18
200-day SMA
Buy
Level
$3.43
Bollinger Bands (100)
Buy
Level
3.18 - 4.66
Chaikin Money Flow
Buy
Level
54.5M
20-day SMA
Sell
Level
$4.32
Relative Strength Index (RSI14)
Sell
Level
47.52
ADX Line
Buy
Level
15.35
Williams %R
Neutral
Level
-25.8065
50-day SMA
Sell
Level
$4.35
MACD (12, 26)
Sell
Level
-0.10
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
71.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.1464)
Buy
CA Score
(Annual)
Level (0.8051)
Buy
Beneish M-Score
(Annual)
Level (-2.8421)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (0.9531)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Stock Forecast FAQ
In the current month, ORGO has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ORGO average analyst price target in the past 3 months is $6.00.
-
Where Will Organogenesis Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Organogenesis Holdings share price will rise to $6.00 per share over the next 12 months.
-
What Do Analysts Say About Organogenesis Holdings?
Analysts are divided on their view about Organogenesis Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Organogenesis Holdings is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Organogenesis Holdings's Price Target?
The price target for Organogenesis Holdings over the next 1-year time period is forecast to be $6.00 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ORGO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Organogenesis Holdings is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ORGO?
You can purchase shares of Organogenesis Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Organogenesis Holdings shares.
-
What Is The Organogenesis Holdings Share Price Today?
Organogenesis Holdings was last trading at $4.34 per share. This represents the most recent stock quote for Organogenesis Holdings. Yesterday, Organogenesis Holdings closed at $4.21 per share.
-
How To Buy Organogenesis Holdings Stock Online?
In order to purchase Organogenesis Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is TSMC the Best Semiconductor Stock to Buy Now?
The new administration has launched a slew of tariffs, paused…
Rocket Lab Vs Intuitive Machines Stock
The commercialization of outer space is now in full swing,…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 30x
Sell
40
Is NVDA Stock a Buy?
Market Cap: $2.4T
P/E Ratio: 33x
Alerts
Buy
58
AGX alert for Apr 22
Argan [AGX] is up 3.08% over the past day.
Sell
44
INOD alert for Apr 22
Innodata [INOD] is up 5.26% over the past day.
Sell
44
UHS alert for Apr 22
Universal Health Services [UHS] is up 2.73% over the past day.
